ProfileGDS5678 / 1423001_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 74% 73% 74% 77% 79% 75% 75% 75% 75% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0421976
GSM967853U87-EV human glioblastoma xenograft - Control 24.9598575
GSM967854U87-EV human glioblastoma xenograft - Control 34.8207974
GSM967855U87-EV human glioblastoma xenograft - Control 44.8505873
GSM967856U87-EV human glioblastoma xenograft - Control 54.8666174
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0955877
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3938779
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9417875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9418875
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9549675
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9499375
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8875174
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.957375
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9492575